Copyright © 2012 Dinah Zur and Anat Loewenstein. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. Y. M. Paulus and R. F. Gariano, “Diabetic retinopathy: a growing concern in an aging population,” Geriatrics, vol. 64, no. 2, pp. 16–20, 2009. View at Scopus
2. A. D. Deshpande, M. Harris-Hayes, and M. Schootman, “Epidemiology of diabetes and diabetes-related complications,” Physical Therapy, vol. 88, no. 11, pp. 1254–1264, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
3. R. Klein, M. D. Knudtson, K. E. Lee, R. Gangnon, and B. E. K. Klein, “The wisconsin epidemiologic study of diabetic retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes,” Ophthalmology, vol. 116, no. 3, pp. 497–503, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
4. “Early treatment diabetic retinopathy study research group: photocoagulation for diabetic macular edema: early treatment diabetic retinopathy study report number 1,” Archives of Ophthalmology, vol. 103, no. 12, pp. 1796–1806, 1985.
5. Diabetes Control and Complications Trial Research Group, “The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus,” The New England Journal of Medicine, vol. 329, pp. 977–986, 1993.
6. UK Prospective Diabetes Study Group, “Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38,” British Medical Journal, vol. 317, pp. 703–713, 1998. View at Scopus
7. “Early treatment diabetic retinopathy study research group: photocoagulation for diabetic macular edema: early treatment diabetic retinopathy study report number 1,” Archives of Ophthalmology, vol. 103, no. 12, pp. 1796–1806, 1985.
8. Diabetic Retinopathy Clinical Research Network (DRCR.net), R. W. Beck, A. R. Edwards, et al., “Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabeticmacular edema,” Archives of Ophthalmology, vol. 127, no. 3, pp. 245–251, 2009.
9. L. P. Aiello, S. E. Bursell, A. Clermont et al., “Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor,” Diabetes, vol. 46, no. 9, pp. 1473–1480, 1997. View at Scopus
10. D. A. Antonetti, A. J. Barber, L. A. Hollinger, E. B. Wolpert, and T. W. Gardner, “Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors,” Journal of Biological Chemistry, vol. 274, no. 33, pp. 23463–23467, 1999. View at Publisher · View at Google Scholar · View at Scopus
11. D. R. Senger, S. J. Galli, A. M. Dvorak, C. A. Perruzzi, V. Susan Harvey, and H. F. Dvorak, “Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid,” Science, vol. 219, no. 4587, pp. 983–985, 1983. View at Scopus
12. T. S. Kern, “Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy,” Experimental diabetes research, vol. 2007, p. 95103, 2007. View at Scopus
13. L. G. Tsaprouni, K. Ito, N. Punchard, and I. M. Adcock, “Triamcinolone acetonide and dexamethasome suppress TNF-α-induced histone H4 acetylation on lysine residues 8 and 12 in mononuclear cells,” Annals of the New York Academy of Sciences, vol. 973, pp. 481–483, 2002. View at Scopus
14. T. Yoshimura, K.-H. Sonoda, M. Sugahara et al., “Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases,” Plos ONE, vol. 4, no. 12, 2009. View at Publisher · View at Google Scholar · View at PubMed
15. H. Funatsu, H. Noma, T. Mimura, S. Eguchi, and S. Hori, “Association of vitreous inflammatory factors with diabetic macular edema,” Ophthalmology, vol. 116, no. 1, pp. 73–79, 2009. View at Publisher · View at Google Scholar · View at PubMed
16. D. A. Antonetti, A. J. Barber, S. Khin, E. Lieth, J. M. Tarbell, and T. W. Gardner, “Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content. Vascular endothelial growth factor decreases occludin in retinal endothelial cells,” Diabetes, vol. 47, no. 12, pp. 1953–1959, 1998.
17. A. M. Joussen, V. Poulaki, M. L. Le et al., “A central role for inflammation in the pathogenesis of diabetic retinopathy,” The FASEB Journal, vol. 18, no. 12, pp. 1450–1452, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
18. M. Nauck, G. Karakiulakis, A. Perruchoud, E. Papakonstantinou, and M. Roth, “Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells,” European Journal of Pharmacology, vol. 341, no. 2-3, pp. 309–315, 1998. View at Publisher · View at Google Scholar · View at Scopus
19. M. Nauck, M. Roth, M. Tamm et al., “Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids,” American Journal of Respiratory Cell and Molecular Biology, vol. 16, no. 4, pp. 398–406, 1997.
20. Diabetic Retinopathy Clinical Research Network, “A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema,” Ophthalmology, vol. 115, no. 9, pp. 1447–1449, 2008.
21. J. B. Jonas, I. Kreissig, and R. Degenring, “Intraocular pressure after intravitreal injection of triamcinolone acetonide,” British Journal of Ophthalmology, vol. 87, no. 1, pp. 24–27, 2003. View at Publisher · View at Google Scholar · View at Scopus
22. J. B. Jonas, R. Degenring, U. Vossmerbauemer, and B. Kamppeter, “Frequency of cataract surgery after intravitreal injection of high-dosage triamcinolone acetonide,” European Journal of Ophthalmology, vol. 15, no. 4, pp. 462–464, 2005. View at Scopus
23. L. P. Aiello, S. E. Bursell, A. Clermont et al., “Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor,” Diabetes, vol. 46, no. 9, pp. 1473–1480, 1997. View at Scopus
24. Q. D. Nguyen, S. Tatlipinar, S. M. Shah et al., “Vascular endothelial growth factor is a critical stimulus for diabetic macular edema,” American Journal of Ophthalmology, vol. 142, no. 6, pp. 961–e4, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
25. P. Massin, F. Bandello, J. G. Garweg et al., “Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study,” Diabetes Care, vol. 33, no. 11, pp. 2399–2405, 2010. View at Publisher · View at Google Scholar · View at PubMed
26. D. S. Boyer, J. Sy, A. C. Rundle, et al., Ranibizumab for Vision Loss due to Diabetic Macular Edema—Results of two Phase III Randomized trials, American Diabetes Association 71st Scientific Sessions, San Diego, Calif, USA, 2011.
27. J. F. Arevalo, J. G. Sanchez, L. Wu, et al., “Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American collaborative retina study group at 24 months: the Pan-American collaborative retina study group at 24 months,” Ophthalmology, vol. 116, no. 8, pp. 1488–1497, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
28. M. Michaelides, A. Kaines, R. D. Hamilton et al., “A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT Study). 12-month data: report 2,” Ophthalmology, vol. 117, no. 6, pp. 1078–1086, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
29. W. K. Se, H. -S. Sa, Y. C. Hee, and I. K. Jong, “Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema,” Archives of Ophthalmology, vol. 124, no. 5, pp. 653–658, 2006.
30. Q. D. Nguyen, S. M. Shah, A. A. Khwaja et al., “Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study,” Ophthalmology, vol. 117, no. 11, pp. 2146–2151, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
31. M. J. Elman, N. M. Bressler, H. Qin et al., “Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema,” Ophthalmology, vol. 118, no. 4, pp. 609–614, 2011. View at Publisher · View at Google Scholar · View at PubMed
32. P. Mitchell, F. Bandello, U. Schmidt-Erfurth et al., “The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema,” Ophthalmology, vol. 118, no. 4, pp. 615–625, 2011. View at Publisher · View at Google Scholar · View at PubMed
33. J. Googe, A. J. Brucker, N. M. Bressler et al., “Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation,” Retina, vol. 31, no. 6, pp. 1009–1027, 2011. View at Publisher · View at Google Scholar · View at PubMed
34. M. Soheilian, A. Ramezani, A. Obudi et al., “Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema,” Ophthalmology, vol. 116, no. 6, pp. 1142–1150, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
35. K. A. Solaiman, M. M. Diab, and M. Abo-Elenin, “Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema,” Retina, vol. 30, no. 10, pp. 1638–1645, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus